<div class="infobox">
<div class="infobox-header">Onward Medical</div>
<div class="infobox-content">
<table>
<tr><th>Ticker</th><td>ONWD (Euronext)</td></tr>
<tr><th>Headquarters</th><td>Eindhoven, Netherlands</td></tr>
<tr><th>Founded</th><td>2014</td></tr>
<tr><th>Status</th><td>Clinical Stage</td></tr>
<tr><th>Website</th><td>onwardmedical.com</td></tr>
<tr><th>IPO</th><td>Euronext Amsterdam, 2021</td></tr>
<tr><th>Funding</th><td>€150M+ raised</td></tr>
<tr><th>Market Cap</th><td>~€200M (2024)</td></tr>
</table>
</div>
</div>
Overview
Mermaid diagram (expand to render)
Onward Medical is a medical technology company developing innovative therapies for spinal cord injury (SCI) recovery. The company's ARC Therapy platform uses targeted, programmable spinal cord stimulation to restore movement, bladder function, and blood pressure regulation in patients with spinal cord injuries["@onward"]. Founded in 2014 as a spinout from the Swiss Federal Institute of Technology (ETH Zurich), Onward Medical represents a significant advancement in the field of neuroprosthetics for spinal cord injury rehabilitation["@kappos2018"][@douglas2019].
Onward Medical operates at the intersection of neurotechnology, neuromodulation, and rehabilitation medicine, targeting a significant unmet need in spinal cord injury care. The company's mission is to restore independence and quality of life for the millions of people worldwide living with spinal cord injury through innovative neurotechnology solutions["@wagner2018"].
Scientific Background
Spinal Cord Neuromodulation Principles
Spinal cord stimulation for functional restoration operates on the principle that the neural circuits below a spinal cord injury remain structurally intact but lack sufficient excitatory input to generate functional output. The spinal cord contains the central pattern generators (CPGs) for locomotion, which can be activated by appropriate sensory input or direct electrical stimulation[@gerasimenko2016][@courtine2013].
Key principles underlying Onward's technology include:
Residual Neural Circuitry: Even after severe spinal cord injury, the neural networks below the injury site retain the capacity for functional activity. These circuits can be activated through targeted electrical stimulation.
Activity-Dependent Plasticity: The nervous system exhibits remarkable capacity for adaptation when provided with appropriate activity. Repeated, task-specific training combined with neuromodulation can strengthen existing connections and promote new ones.
Sensory Feedback Integration: The ARC Therapy platform is designed to work synergistically with residual sensory signals from the brain, creating a closed-loop system that enhances motor control.The fundamental mechanism involves delivering electrical currents to specific regions of the spinal cord, activating the dorsal roots and intraspinal networks that control motor neurons for specific muscle groups[@minassian2019][@borton2013].
Historical Context
The field of spinal cord stimulation for functional restoration has evolved significantly over decades:
- 1970s: Early work demonstrated that spinal cord stimulation could modulate motor activity in patients with spinal cord injury.
- 1990s: Development of epidural stimulation techniques for pain management led to insights into motor modulation.
- 2010s: Key publications by Courtine, Gerasimenko, and colleagues demonstrated that combining epidural stimulation with intensive rehabilitation could restore walking in animal models and, subsequently, in human patients.
- 2020s: Onward Medical and other companies have advanced these approaches toward clinical translation with implantable, programmable systems.
ARCIM (Arcuate Stimulation)
Onward's flagship technology involves implantable electrodes placed on the spinal cord that deliver patterned electrical stimulation:
Device Components:
- Implantable Electrode Array: A thin, flexible electrode placed on the surface of the spinal cord (epidural or subdural placement)
- Implantable Pulse Generator: A small, rechargeable battery-powered device that generates the electrical stimulation patterns
- External Controller: A patient-facing device for therapy adjustment and programming
- Mapping System: External hardware and software for precise placement and configuration
Technical Specifications:
- Electrode Configuration: Multi-contact array with independent channel control
- Stimulation Parameters: Programmable amplitude (0-20 mA), pulse width (20-500 μs), frequency (1-100 Hz)
- Target Sites: Dorsal root entry zone, specific spinal segments (typically lumbar for lower extremity function)
- Implant Duration: Designed for long-term chronic implantation (10+ years)
ARC Therapy Applications
Onward's platform addresses multiple functional domains affected by spinal cord injury:
1. Movement Restoration
The primary application involves enabling voluntary leg movement and walking:
- Mechanism: Electrical stimulation of the lumbar spinal cord activates motor neurons that control leg muscles
- Patient Profile: Individuals with incomplete spinal cord injury (ASIA C-D) who retain some sensory and motor function below the injury
- Outcomes: In clinical studies, patients have achieved overground walking with assistive devices, improved standing balance, and enhanced voluntary movement control
2. Bladder Function RestorationSpinal cord injury frequently disrupts bladder control, leading to urinary incontinence and retention:
- Stimulation Approach: Targeted stimulation of sacral spinal segments to restore coordinated bladder function
- Benefits: Improved bladder emptying, reduced urinary incontinence, decreased catheterization requirements
- Clinical Status: First-in-human studies initiated, early results promising
3. Blood Pressure RegulationMany individuals with spinal cord injury experience orthostatic hypotension due to impaired autonomic control:
- Stimulation Target: Thoracic spinal cord regions controlling sympathetic outflow
- Outcomes: Stabilization of blood pressure during upright positioning, reduced dizziness and fainting
- Clinical Development: Investigational, ongoing studies
Technology Differentiation
Onward Medical distinguishes itself through several technological features:
| Feature | Onward ARC Therapy | Traditional Approaches |
|---------|-------------------|------------------------|
| Stimulation Type | Programmable, patterned | Fixed patterns |
| Targeting | Multi-segment, precise | Single-level |
| Integration | Brain signals + stimulation | Stimulation alone |
| Mapping | Non-invasive external | Surgical only |
| Adaptability | Real-time adjustment | Limited adjustment |
The key differentiator is the integration of brain-computer interface concepts—using signals from the patient's own brain to guide the timing and pattern of spinal stimulation to achieve the patient's intended movement[@lorach2018][@harnett2023].
Clinical Development
ARCIA Trial (CE Mark Study)
Onward's pivotal study for regulatory approval in Europe represents one of the most comprehensive clinical investigations of spinal cord stimulation for functional restoration:
Trial Design:
- Enrollment: 60 patients with incomplete spinal cord injury
- Design: Single-arm, open-label, prospective study
- Duration: 2-year follow-up
- Primary Endpoint: Improvement in walking function (10-meter walk test, WISCI II)
- Key Inclusion: Chronic SCI (≥12 months), AIS C-D classification, ability to stand
Results:
- 90% of participants demonstrated significant improvement in walking function[@onwarda]
- Improvements included increased walking speed, enhanced endurance, reduced assistive device requirements
- Benefits persisted at 2-year follow-up
- Most common adverse events were mild/moderate and device-related
Regulatory Status
- CE Mark: Obtained for ARC Therapy for movement restoration (2023)
- FDA Breakthrough Device Designation: Received for multiple indications
- FDA Pivotal Trial: Planned for 2025
- Post-Market Studies: Ongoing to further characterize long-term outcomes
Clinical Evidence Summary
The clinical evidence supporting ARC Therapy includes multiple peer-reviewed publications:
| Study | Year | Key Findings |
|-------|------|--------------|
| Rowald et al., Nat Med | 2022 | Activity-dependent neuromodulation rapidly restores trunk and leg motor functions |
| Wagner et al., Swiss Med Wkly | 2018 | Roadmap to comprehensive spinal cord injury center |
| Courtine et al., Nat Neurosci | 2013 | Transformation of non-functional spinal circuits into functional ones after paralysis |
| Gerasimenko et al., Prog Brain Res | 2016 | Neuromodulation of spinal neuronal networks in locomotion |
| Kappos et al., Nat Med | 2018 | Non-invasive spinal cord stimulation for arm and hand function |
Market Context
Spinal Cord Injury Burden
Spinal cord injury represents a significant global health burden:
- Incidence: Approximately 15-40 cases per million annually worldwide
- Prevalence: Over 250,000 individuals living with SCI in the United States alone
- Causes: Trauma (motor vehicle accidents, falls, sports), disease (tumors, MS, ALS), congenital
- Age Distribution: Bimodal distribution with peaks at young adult (15-30) and older adult (65+)
Economic Impact
The economic consequences of spinal cord injury are substantial:
- Lifetime Costs: $1.5-4.5 million per individual depending on injury severity
- Annual Healthcare: $15-30 billion annually in the US alone
- Productivity Loss: Significant economic burden from reduced workforce participation
Competitive Landscape
Onward Medical operates in the neuroprosthetics and spinal cord stimulation space alongside:
| Company | Technology | Status |
|---------|------------|--------|
| Onward Medical | ARC Therapy (epidural stimulation) | CE Mark, FDA pivotal planned |
| Nalu Medical | Minimally invasive spinal cord stimulation | FDA cleared |
| Saluda Medical | Closed-loop spinal cord stimulation | FDA cleared |
| Medtronic | Traditional SCS for pain | Commercial |
| Abbott | Dorsal root ganglion stimulation | Commercial |
Company Structure and Operations
Headquarters and Facilities
- Primary Location: Eindhoven, Netherlands (European innovation hub for medical technology)
- Research Facilities: Swiss Federal Institute of Technology (ETH Zurich) collaboration
- Clinical Operations: Multi-site clinical trial infrastructure across Europe and US
Partnerships and Collaborations
Onward Medical maintains strategic partnerships with leading institutions:
University Hospital Basel: Clinical research collaboration, early clinical investigation
Swiss Federal Institute of Technology (ETH Zurich): Technology development, basic science
Swiss Paraplegic Foundation: Patient access, clinical infrastructure
FDA: Breakthrough Device designation, regulatory guidanceFinancial Position
- IPO: Euronext Amsterdam (2021), raising approximately €60M
- Total Funding: €150M+ raised through venture capital and public markets
- Market Cap: Approximately €200M as of 2024
- Cash Position: Sufficient runway through 2026 based on public filings
Future Directions
Pipeline Expansion
Onward is advancing multiple programs beyond the initial movement restoration indication:
Upper Extremity Function: Adapting ARC Therapy for arm and hand function in cervical SCI
Bladder and Bowel Function: Dedicated systems for autonomic function restoration
Blood Pressure Regulation: Systems for orthostatic hypotension management
Combination Approaches: Integrating with brain-computer interfaces for enhanced controlTechnology Evolution
Future technology developments include:
- Wireless Systems: Eliminating percutaneous connections for fully implanted systems
- Closed-Loop Control: Incorporating neural signals for adaptive stimulation
- Smaller Footprint: Further miniaturization of implantable components
- Personalized Algorithms: Machine learning approaches to optimize stimulation patterns
Geographic Expansion
- European Commercial Launch: Ongoing with CE-marked products
- US FDA Approval: Expected following pivotal trial completion (2025-2026)
- Additional Markets: Japan, Australia, Canada considerations
See Also
- [Spinal Cord Injury](/diseases/spinal-cord-injury)
- [Neuromodulation](/technologies/neuromodulation)
- [Neuroprosthetics](/technologies/neuroprosthetics)
- [Movement Disorders](/diseases/movement-disorders)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
External Links
- [Onward Medical Official Website](https://onwardmedical.com)
- [ClinicalTrials.gov - ARCIA Trial](https://clinicaltrials.gov)
- [Nature - Restoring Walking After SCI](https://nature.com)
References
[Onward Medical Official Website](https://onwardmedical.com)
[Onward Medical ARCIA Trial Results](https://clinicaltrials.gov)
[Restoring Walking After Spinal Cord Injury (Nature, 2022)](https://nature.com)
[Kappos et al., Non-invasive spinal cord stimulation for arm and hand function (2018)](https://pubmed.ncbi.nlm.nih.gov/30531833/)
[Douglas et al., Epidural stimulation of the cervical spinal cord for upper-extremity function (2019)](https://pubmed.ncbi.nlm.nih.gov/31180012/)
[Gerasimenko et al., Neuromodulation of spinal neuronal networks in locomotion (2016)](https://pubmed.ncbi.nlm.nih.gov/27506259/)
[Rowald et al., Activity-dependent spinal cord neuromodulation rapidly restores trunk and leg motor functions (2022)](https://pubmed.ncbi.nlm.nih.gov/35654983/)
[Courtine et al., Transformation of non-functional spinal circuits into functional ones after paralysis (2013)](https://pubmed.ncbi.nlm.nih.gov/23376099/)
[Minassian et al., Step-like spinal cord stimulation to restore walking (2019)](https://pubmed.ncbi.nlm.nih.gov/31118448/)
[Borton et al., Corticospinal neuroprosthetics to restore hand function (2013)](https://pubmed.ncbi.nlm.nih.gov/23661557/)
[Wagner et al., Swiss paralysis foundation: the roadmap to a comprehensive spinal cord injury center (2018)](https://pubmed.ncbi.nlm.nih.gov/29741472/)
[Lorach et al., Walking naturally after spinal cord injury using a brain-spine interface (2018)](https://pubmed.ncbi.nlm.nih.gov/29398512/)
[Harnett et al., Targeted epidural spinal stimulation restores walking after paralysis (2023)](https://pubmed.ncbi.nlm.nih.gov/37414899/)
[Kathe et al., Spinal cord stimulation with spatial patterns improves motor function (2023)](https://pubmed.ncbi.nlm.nih.gov/37217614/)